Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth f
about
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patientsCancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Progress in immunotherapy for non-small cell lung cancerStrengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials.Targeted immunotherapy for non-small cell lung cancer.Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.Immunotherapy for lung cancers.Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for ImmunotherapyThe androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiationCIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.Immunosenescence and gender: a study in healthy Cubans.Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies.CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Non-small-cell lung carcinoma vaccines in clinical trials.Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.Epidermal growth factor vaccine in non-small-cell lung cancer.Targeting the immune system in the treatment of non-small-cell lung cancer.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients.Actual status of therapeutic vaccination in non-small cell lung cancerMoving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.Immune Therapy.Active-specific immunotherapy for non-small cell lung cancer.Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.An enzyme immunoassay for determining epidermal growth factor (EGF) in human serum samples using an ultramicroanalytical system.New Approaches in Immunotherapy for the Treatment of Lung Cancer.Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model.A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
P2860
Q21245661-17E6A3C1-5A24-44B1-91E8-A39008F1E976Q26778150-E5C9ADCF-F097-4FD8-8767-387E97755DC4Q26865725-78543947-B659-4FEF-B2F1-DB67141A9059Q31050197-04922125-2E14-4F27-9525-3607CCF29C31Q33585089-085A0D35-F158-44F1-B8FF-4B6AB0842C88Q33653836-C32D7B90-1300-4D01-8FB1-3917AE5052F3Q34449304-645D7BCA-E8A1-4AA6-A796-BE8EE0290E9CQ34490460-13AEBB42-3944-4B90-A977-8927FCD8AE45Q34557611-80B999FD-1080-492A-953C-09FDD342AD15Q35623476-71824735-9F52-482D-9397-268FB26FE2A2Q36625406-2245A3D1-6006-4E46-9BCE-1A27BDD21390Q36697093-39162E1F-4C02-491F-A571-E86BF9B2BB20Q36849784-141E8CFB-DFD3-41DE-A801-902D29E520E8Q36885178-2D1DB862-5CAB-4BAA-9B9A-D32521C1955BQ37256078-919A3732-217A-493D-B696-7DE0BA18AA21Q37354177-F912645F-E1A0-48FC-90E7-E8F8AD48A538Q37369449-85A87C83-DBE7-4082-8B81-F42454904DC4Q37639755-A1752AD0-9D27-4F47-92C0-18A42DCD6B4EQ37695065-E07F95BF-2C89-4D87-8EA0-9BDEE7F36D47Q37892598-DA22F546-7284-498E-BA85-94AEFC508A9FQ37894088-40484EC1-C6E3-4B4B-AE30-16F0183244C6Q38002466-C0F76E0B-D5A3-4DDE-BF51-65E86C322C14Q38128228-A19C3180-91AC-4DCF-85D8-CDE2CCE6AFCEQ38143201-09598528-CD29-4700-A634-F6A2084E196EQ38207923-7A15D5DE-FA41-47A5-8033-86C6E9661DA0Q38223388-7DDE88C9-BBBF-49CB-9EDD-82A7FE50607DQ38245669-E64F26C8-E5CC-4989-BF58-A94CB93B8325Q38447986-3D36A23E-E409-4E00-8A7D-A9136834573FQ38669273-7A82BC83-86C8-4EBA-A517-0DA1258B7051Q40342047-F57AB567-F3EF-4B4F-A95C-FC1D1D4D7E8DQ41109485-97EFC09F-00C4-492C-9904-9C8F78B671ABQ41258130-6AF76FB7-ADC9-4DAE-B686-3E697C039A3DQ45367630-96E88B5A-624A-437A-B116-E5007F2AE1DEQ47299048-31B6438A-6605-4470-BDF7-0D1FEB25819AQ51498835-9C9C1BB3-723A-4BC5-9036-C978E34FDC0AQ52871134-9BAC2CB1-1CBF-4632-B24F-11430AD3C3A3Q55000389-B47A4380-0E26-499A-AA6C-13105F679466Q55026505-1CBD4CDC-F525-4390-A768-87C15825F6B6Q55026796-1D888A7E-EFD2-4363-9608-8FBE1FD752DEQ55045138-B7454003-C220-42AE-864E-63AB3A1E2F97
P2860
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth f
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Effective inhibition of the ep ...... ed with the epidermal growth f
@en
Effective inhibition of the ep ...... ed with the epidermal growth f
@nl
type
label
Effective inhibition of the ep ...... ed with the epidermal growth f
@en
Effective inhibition of the ep ...... ed with the epidermal growth f
@nl
prefLabel
Effective inhibition of the ep ...... ed with the epidermal growth f
@en
Effective inhibition of the ep ...... ed with the epidermal growth f
@nl
P2093
P1476
Effective inhibition of the ep ...... ed with the epidermal growth f
@en
P2093
Agustín Lage
Ana de la Torre
Beatriz García
Carmen Viada
Elia Neninger
Gisela González
Idrissa Leonard
Rocío Martínez
Tania Crombet
Zaima Mazorra
P304
P356
10.1158/1078-0432.CCR-07-1050
P407
P577
2008-02-01T00:00:00Z